CBI has successfully built and maintained a franchise in the Post-Approval space with unmatched research and industry admired speakers and continues that tradition for 2010!
Post-approval studies continue to be an area of increasing importance given the payor power and regulatory requirements. It is also estimated that outsourcing postmarketing studies exceeds $1 billion (according to Dipti Amin, senior vice president, drug safety and medical affairs, Quintiles – Pharma Outsourcing, Oct. 12, 2009). The 2010 forum examines the evolving post-approval landscape and discusses FMV in Phase IV and Registries, impacts of the Sunshine Act, payor requirements and much more!
Don't miss the opportunity to network with industry leaders within pharma, biotech, medical device, CRO, academia, government and technology providers surrounding the latest post-approval studies issues.
Post-approval studies continue to be an area of increasing importance given the payor power and regulatory requirements. It is also estimated that outsourcing postmarketing studies exceeds $1 billion (according to Dipti Amin, senior vice president, drug safety and medical affairs, Quintiles – Pharma Outsourcing, Oct. 12, 2009). The 2010 forum examines the evolving post-approval landscape and discusses FMV in Phase IV and Registries, impacts of the Sunshine Act, payor requirements and much more!
Don't miss the opportunity to network with industry leaders within pharma, biotech, medical device, CRO, academia, government and technology providers surrounding the latest post-approval studies issues.
